Clinical Trial Update: NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) [Phase 3]

View source ↗

Summary

A Phase 3 trial in low-risk triple-negative early breast cancer is evaluating neoadjuvant sacituzumab govitecan alone versus sacituzumab govitecan plus pembroli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Pembrolizumab (Keytruda) (pembrolizumab)
• Sacituzumab Govitecan (Trodelvy) (sacituzumab govitecan)

Snippet

Sponsor: West German Study Group | Conditions: Triple Negative Breast Cancer | Phase 3 | Status: RECRUITING